

# Misako Nagasaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/147541/publications.pdf>

Version: 2024-02-01

83  
papers

1,922  
citations

279798

23  
h-index

302126

39  
g-index

83  
all docs

83  
docs citations

83  
times ranked

2215  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 52-59.	2.6	11
2	NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. <i>Trends in Cancer</i> , 2022, 8, 242-258.	7.4	24
3	Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. <i>Lung Cancer</i> , 2022, 164, 52-55.	2.0	8
4	Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. <i>Journal of Thoracic Oncology</i> , 2022, 17, 182-185.	1.1	5
5	Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	1
6	Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2020-2029.	7.0	18
7	ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?. <i>Lung Cancer: Targets and Therapy</i> , 2022, Volume 13, 13-21.	2.7	2
8	Generalizability of ORIENT-11 trial results to a US standard of care cohort with advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2022, , .	2.4	2
9	A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2022, 106, 102393.	7.7	18
10	NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. <i>Cancer Medicine</i> , 2022, 11, 2541-2549.	2.8	22
11	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C Mutant Cancers. <i>Cancer Research Communications</i> , 2022, 2, 342-352.	1.7	12
12	Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. <i>Lung Cancer: Targets and Therapy</i> , 2022, Volume 13, 33-45.	2.7	6
13	Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 3464-3472.	7.0	8
14	Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. <i>Drugs</i> , 2022, 82, 979-987.	10.9	35
15	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 740-763.	1.1	115
16	PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy. <i>Clinical Lung Cancer</i> , 2021, 22, e51-e53.	2.6	6
17	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100116.	1.1	12
18	Identification of Novel CDH1-NRG2± and F11R-NRG2± Fusions in NSCLC Plus Additional Novel NRG2± Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100132.	1.1	7

#	ARTICLE	IF	CITATIONS
19	STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. JTO Clinical and Research Reports, 2021, 2, 100125.	1.1	7
20	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Scientific Reports, 2021, 11, 5639.	3.3	1
21	Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2021, 16, 532-536.	1.1	23
22	Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer. Clinical Lung Cancer, 2021, 22, e842-e850.	2.6	9
23	Forget me not â€“ Incorporating standard chemotherapy in an exciting era of clinical trials. Oral Oncology, 2021, 116, 105160.	1.5	0
24	Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.. Journal of Clinical Oncology, 2021, 39, 3003-3003.	1.6	37
25	Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer, 2021, 20, 82.	19.2	58
26	Gastrostomy tube dependence and patientâ€™reported quality of life outcomes based on type of treatment for human papillomavirusâ€associated oropharyngeal cancer: Systematic review and metaâ€analysis. Head and Neck, 2021, 43, 3681-3696.	2.0	5
27	Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer, 2021, 157, 147-155.	2.0	30
28	Abstract 1058: Inhibition of nuclear transport protein XPO1 potentiates the effect of KRASG12Cinhibitors. , 2021, , .		1
29	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer, 2021, 158, 126-136.	2.0	53
30	Characterization of KRAS Mutation Subtypes in Nonâ€small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 2577-2584.	4.1	66
31	Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835.	5.9	41
32	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusionâ€Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	1.6	32
33	Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 2021, 160, 92-98.	2.0	3
34	p16 positive oropharyngeal small cell cancer: A case report. Oral Oncology, 2021, 121, 105391.	1.5	2
35	Will the clinical development of 4th-generation â€œdouble mutant activeâ€ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. Translational Oncology, 2021, 14, 101191.	3.7	24
36	Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	3

#	ARTICLE	IF	CITATIONS
37	KRAS Inhibitors“ yes but what next? Direct targeting of KRAS“ vaccines, adoptive T cell therapy and beyond. <i>Cancer Treatment Reviews</i> , 2021, 101, 102309.	7.7	37
38	Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 115-122.	2.7	13
39	Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 103-114.	2.7	6
40	Incidence of Second Primary Lung Cancer After Low-Dose Computed Tomography vs Chest Radiography Screening in Survivors of Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 1071.	2.2	15
41	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 133-138.	2.7	11
42	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 247-254.	2.6	48
43	Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?. <i>Oral Oncology</i> , 2020, 101, 104435.	1.5	2
44	Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 237.	4.1	23
45	Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 305-311.	0.4	9
46	Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer“ A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102841.	4.4	28
47	Is NRG2± Fusion a “Doppelgänger“ to NRG1±/2 Fusions in Oncology?. <i>Journal of Thoracic Oncology</i> , 2020, 15, 878-880.	1.1	4
48	A Catalog of 5™ Fusion Partners in ROS1-Positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100048.	1.1	9
49	A user™s guide to lorlatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102969.	4.4	26
50	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor“Refractory ALK-Positive or ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1484-1496.	1.1	43
51	The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). <i>Oral Oncology</i> , 2020, 109, 104744.	1.5	4
52	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020, 145, 186-194.	2.0	68
53	Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 175.	2.7	4
54	KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. <i>Cancer Treatment Reviews</i> , 2020, 84, 101974.	7.7	143

#	ARTICLE	IF	CITATIONS
55	COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report. <i>Lung Cancer</i> , 2020, 141, 78-81.	2.0	7
56	<p>Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 13-18.	2.7	6
57	Catalog of 5â€™ Fusion Partners in ALK-positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100015.	1.1	62
58	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9504-9504.	1.6	91
59	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 2521-2534.	2.8	15
60	Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report. <i>Oral Oncology</i> , 2019, 99, 104350.	1.5	6
61	&lt;p&gt;A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors&lt;/p&gt;. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 95-105.	2.7	3
62	Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. <i>Frontiers in Microbiology</i> , 2019, 10, 2110.	3.5	17
63	Unleash the power of the mighty T cells-basis of adoptive cellular therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 1-12.	4.4	20
64	Neuregulin 1 Fusionâ€™Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1354-1359.	1.1	25
65	Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinomaâ€™A single institution analysis of 54 patients. <i>Clinical Otolaryngology</i> , 2019, 44, 639-643.	1.2	5
66	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. <i>Anticancer Research</i> , 2019, 39, 781-790.	1.1	25
67	A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20061-e20061.	1.6	0
68	Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. <i>Oral Oncology</i> , 2018, 80, 100-102.	1.5	6
69	Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 63-70.	2.4	172
70	Liquid Biopsy to Identify Actionable Genomic Alterations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 978-997.	3.8	54
71	Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 85-90.	2.7	20
72	Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. <i>Frontiers in Microbiology</i> , 2018, 9, 1651.	3.5	48

#	ARTICLE	IF	CITATIONS
73	Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1278-1281.	0.5	9
74	Radiation therapy and immune-related side effects in patients treated with PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	1.6	1
75	Histologic Transformation in NSCLC with PD-1 therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, e133-e134.	1.1	9
76	Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e713-e717.	1.9	8
77	<i>EGFR</i> -Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline <i>EGFR</i> T790M Testing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1188-1192.	4.9	7
78	Toxicities associated with checkpoint inhibitor immunotherapy: The Karmanos Cancer Center experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14575-e14575.	1.6	1
79	PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. , 2016, 4, 83.		31
80	Cancer Immunology and Immunotherapy. <i>Anticancer Research</i> , 2016, 36, 5593-5606.	1.1	69
81	Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIa) <i>EGFR</i> -mutant NSCLC. <i>Lung Cancer: Targets and Therapy</i> , 0, Volume 13, 47-52.	2.7	0
82	African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. <i>Head and Neck</i> , 0, , .	2.0	3
83	Clinical progress of <i>KRAS</i> -targeted therapies: what next?. <i>Future Medicinal Chemistry</i> , 0, , .	2.3	2